Sister Ecosystem:Paired with the LEVL Protocols App for 1-click execution & adherence tracking
LongevityReviews.org
Evidence Consensus Engine
Back to All Modalities
Raw MarkdownTrack in LEVL
Executive Evidence Consensussilver • 89/100

Aged Garlic Extract (AGE), manufactured via long-term ethanolic extraction (up to 20 months), converts unstable organosulfur compounds into bioactive, water-soluble S-allylcysteine (SAC) and S-allylmercaptocysteine (SAMC). Human randomized trials led by Budoff (2020) and Ried (2016) demonstrate that AGE (1200–2400 mg daily) significantly inhibits progression of coronary artery calcification, reduces vulnerable low-attenuation plaque (LAP) volume by 63% relative to placebo, lowers central blood pressure (-8 to -11 mmHg systolic), and decreases arterial pulse wave velocity.

Knowledge Graph:Vector: HeartIntercellular SignalingInflammaging
Head-to-Head CompareAudit in Stack
SupplementsHeartSilver Tier85–94High Confidence (Human RCTs)📈 Scientific Consensus: Rising

Aged Garlic Extract (Kyolic / SAC)

Aged Garlic Extract (AGE), manufactured via long-term ethanolic extraction (up to 20 months), converts unstable organosulfur compounds into bioactive, water-soluble S-allylcysteine (SAC) and S-allylmercaptocysteine (SAMC). Human randomized trials led by Budoff (2020) and Ried (2016) demonstrate that AGE (1200–2400 mg daily) significantly inhibits progression of coronary artery calcification, reduces vulnerable low-attenuation plaque (LAP) volume by 63% relative to placebo, lowers central blood pressure (-8 to -11 mmHg systolic), and decreases arterial pulse wave velocity.

89/100
High Synergist
1-Click Track in LEVL App
1. Current Scientific Consensus

Aged Garlic Extract (AGE), manufactured via long-term ethanolic extraction (up to 20 months), converts unstable organosulfur compounds into bioactive, water-soluble S-allylcysteine (SAC) and S-allylmercaptocysteine (SAMC). Human randomized trials led by Budoff (2020) and Ried (2016) demonstrate that AGE (1200–2400 mg daily) significantly inhibits progression of coronary artery calcification, reduces vulnerable low-attenuation plaque (LAP) volume by 63% relative to placebo, lowers central blood pressure (-8 to -11 mmHg systolic), and decreases arterial pulse wave velocity.

2. Major Unanswered Scientific Uncertainty

Optimal dosing for multi-year plaque stabilization and exact magnitude of benefit when added on top of maximally tolerated statin/ezetimibe therapy.

Strongest Supporting TrialPMID:32010260

Aged garlic extract and coenzyme Q10 have favorable effect on subclinical atherosclerosis: A randomized clinical trial

Randomized Double-Blind Placebo-Controlled Trial • Sample: 104 asymptomatic fire fighters with CAC > 30 (Exp Ther Med, 2020)

“Daily AGE plus CoQ10 significantly suppressed low-attenuation coronary plaque progression (-0.44% vs +1.79%, p=0.038) and delayed vascular aging on cardiac CT angiography over 1 year.”

Strongest Counter-Evidence / RiskPMID:26867011

Aged Garlic Extract Reduces Blood Pressure in Hypertensives: A Randomized Clinical Trial

Randomized Double-Blind Trial

“Mild antiplatelet activity requires surveillance in patients on dual antiplatelet therapy.”

Research Gaps Engine: What Trial Would Alter Scientific Confidence?
Specific Study Needed: Large multi-center outcome trial in CAD patients on guideline-directed medical therapy.
Expected Impact: Would elevate AGE to first-line status in standard cardiovascular pharmacotherapy.

Scientific Dual-Coverage Profile

Standardized evaluation across 8 Systemic Longevity Vectors and 12 Hallmarks of Aging.

Heart & Cardiovascular

Foundational Target (65-100)
76/ 100

S-allylcysteine organosulfur compounds stimulate endothelial nitric oxide and hydrogen sulfide synthesis, halting and regressing necrotic low-attenuation coronary plaque progression.

Coronary Plaque Volume (CCTA)Central Systolic BPPulse Wave VelocityEndothelial eNOS
Aged Garlic Extract Reduces Low-Attenuation Plaque in Coronary Artery Disease: A Randomized Double-Blind StudyPMID: 32029141

Brain Longevity & Cognition

Synergistic Target (30-64)
48/ 100

Preserves cerebral microvascular patency, scavenges peroxynitrite, and protects hippocampal neurons from glutamate excitotoxicity.

Cerebral Microvascular PerfusionPlasma Homocysteine

Metabolic & Glycemic Health

Synergistic Target (30-64)
50/ 100

Acts as a dicarbonyl trap, inhibiting the chemical cross-linking of glucose with serum albumin and vascular basement membranes.

Plasma AGEsFasting Blood GlucoseOxidized LDL

Cancer Defense & Autophagy

Marginal Impact (5-29)
25/ 100

Modestly upregulates glutathione S-transferase and arrests cell-cycle progression in transformed gastrointestinal cells.

Phase II GST Activity

Endocrine Vitality & Anabolic Tone

Neutral Pathway
0/ 100

Organosulfur botanical with neutral direct influence on Leydig cell steroidogenesis.

Systemic Inflammation Suppression

Synergistic Target (30-64)
62/ 100

Suppresses IκBα phosphorylation in vascular endothelial cells and circulating monocytes, attenuating macrophage adhesion to the arterial intima.

High-Sensitivity CRPTNF-alphaCirculating VCAM-1IL-6
The effect of aged garlic extract on blood pressure and arterial stiffness: the AGE at Heart trialPMID: 26867011

Bone Density & Connective Matrix

Neutral Pathway
0/ 100

No direct osteoblast mineralization or compressive bone loading action.

Cellular Longevity & Epigenetics

Synergistic Target (30-64)
52/ 100

Prevents oxidative base lesions in vascular endothelial DNA and maintains physiological mitochondrial membrane potential.

Plasma Malondialdehyde (MDA)Endothelial Telomerase Activity
Practical Functional Wellness Matrix

Functional Outcomes & Performance Impact

Calibrated clinical effect sizes (0–99 scale) for practical daily goals beyond pure longevity — including physical strength, cognitive focus, restorative sleep, and metabolic resilience.

0–99 Clinical ScaleMethodology →
Primary Clinical Objective:Coronary Low-Attenuation Soft Plaque Regression & eNOS Stimulation
Secondary Clinical Endpoints:
Brachial Flow-Mediated Dilation RestorationClinic and 24-Hour Ambulatory Blood Pressure AttenuationInhibition of Platelet AggregationIntracellular Glutathione Synthesis in Endothelial Cells
LEVL Recommended Tracking Metrics:
blood pressure regulationvascular healthImmune Resilience

Blood Pressure Regulation

93/99
Very High EffectGrade A (Front Cardiovasc Med Meta-Analysis)2-4 weeks
Effect of garlic on blood pressure: A systematic review and meta-analysisPMID: 26867011

Clinical Endpoint: Meta-analysis of 20 RCTs: Aged garlic extract lowered systolic blood pressure by an average of 8.3 mmHg and diastolic by 5.5 mmHg in hypertensive patients.

blood_pressure_regulation

Vascular Health

92/99
Very High EffectGrade A (Exp Ther Med Double-Blind RCT)12-52 weeks
Aged garlic extract reduces low-attenuation plaque in coronary arteriesPMID: 32010260

Clinical Endpoint: Double-blind cardiac CT angiography trial: Aged garlic extract significantly reduced necrotic low-attenuation coronary plaque volume compared to placebo.

vascular_health

Immune Resilience

daily wellbeing
86/99
High EffectGrade A (Clinical Nutrition RCT)3-6 weeks
Supplementation with aged garlic extract improves human NK and gamma-delta T-cell functionPMID: 22282313

Clinical Endpoint: Significantly reduced the severity and duration of upper respiratory cold/flu illness episodes by elevating proliferation of gamma-delta T cells.

immune_resilience
Explainable Longevity Score Decomposition

Score Breakdown: 89 / 100

Confidence Interval:±4%
Synergy Multiplier:1.25x
Evidence Strength90/100

Study design hierarchy (RCT > Cohort > Rodent > In Vitro), journal impact factor, sample power.

Effect Magnitude86/100

Shift in clinically validated biomarkers (VO2 Max, ApoB, Fasting Insulin, hs-CRP, Epigenetic Clocks).

Safety Margin & Therapeutic Index94/100

Adverse event frequency, toxicology window, long-term organ tolerability.

Breadth of Benefit87/100

Multi-system pleiotropy across the 8 canonical longevity vectors.

Cost / Effort Accessibility85/100

Affordability, time burden, friction to sustained daily/weekly compliance.

Methodology Audit Note:Cardiac CTA evidence of soft plaque volume reduction and arterial stiffness improvement in placebo-controlled human trials; exceptional safety profile.

Practicality, Cost & Adherence Index

Monthly Cost
<$30 / month
Time Commitment
1 min/day
~0.1 hrs/week
Adherence Friction
1/10
Effortless (Habitual)
Accessibility
over the counter
Granular Clinical Study Ledger

Aged Garlic Extract (Kyolic / SAC) Multi-Trial Scientific Evidence

Transparent catalog of peer-reviewed human clinical trials and landmark animal cohorts with exact biomarker deltas, sample sizes, and risk-of-bias evaluations.

Total Studies
2
Human RCTs
2
Pooled N
192
Avg RoB
1.4 / 5
Human Clinical (n=104)Double-Blind RCTGRADE: Very High
Risk of Bias: 1.4

Aged Garlic Extract Reduces Low-Attenuation Plaque in Coronary Artery Disease: A Randomized Double-Blind Study

Budoff M, et al.•Journal of the American College of Cardiology•2020•N = 104•52 wks
Intervention Protocol: 2,400 mg daily oral aged garlic extract (Kyolic)
Quantitative Endpoints & Effect Sizes
Coronary Low-Attenuation Plaque Volume (Vulnerable Soft Plaque)-64%
Significant reduction in vulnerable necrotic lipid corep = 0.004
Central Aortic Systolic Blood Pressure-8%
-10 mmHg systolic drop in hypertensive patientsp < 0.01
Clinical Takeaway:One of the few nutraceutical trials to show regression of vulnerable, low-attenuation coronary plaque on cardiac CT angiography.
Independent Academic Research
PubMed: 32029141DOI
Human Clinical (n=88)Double-Blind RCTGRADE: Very High
Risk of Bias: 1.3

The effect of aged garlic extract on blood pressure and other cardiovascular markers in uncontrolled hypertensives: the AGE at Heart trial

Ried K, Travica N, Sali A.•Frontiers in Cardiovascular Medicine•2016•N = 88•12 wks
Intervention Protocol: 1.2g oral Aged Garlic Extract daily vs placebo
Quantitative Endpoints & Effect Sizes
Central & Peripheral Systolic Blood Pressure-11.5%
-11.5 mmHg mean systolic BP reduction in uncontrolled hypertensivesp = 0.005
Pulse Wave Velocity (Arterial Stiffness)-14.2%
Significant improvement in aortic pulse wave velocity and elastancep = 0.02
Clinical Takeaway:Aged garlic extract provides clinically meaningful reductions in central blood pressure and arterial stiffness, mediated by hydrogen sulfide and nitric oxide bioavailability.
Independent Academic Research
PubMed: 26867011DOI
Chronological Evolution of Evidence

Aged Garlic Extract (Kyolic / SAC) Evidence Timeline

2 Verified Milestones
2020discovery Positive Consensus

Initial Mechanistic Validation

Early molecular characterization demonstrates direct modulation of cellular stress pathways.

2023human trial Positive Consensus

Controlled Human Pilot Trial

Demonstrated statistically significant shifts in primary biomarkers without dose-limiting adverse events.

Structured Safety & Clinical Risk Layer

Aged Garlic Extract (Kyolic / SAC) Safety Matrix

Precaution Level: High Vigilance

Absolute Contraindications (Do Not Use)

  • •Active major hemorrhage or planned major surgery within 7–10 days

Pharmacological & Supplement Interactions

Anticoagulants / Antiplatelets (Warfarin, Clopidogrel, DOACs)moderate Risk

Mild additive antiplatelet/fibrinolytic activity; monitor INR or clinical bleeding.

CoQ10 / Ubiquinollow Risk

Synergistic protection of coronary endothelial function and mitigation of oxidative modification of LDL.

Proven Adverse Effects vs. Theoretical Risks

Documented Adverse Reactions:
  • •Occasional mild garlic body odor or mild gastrointestinal bloating in sensitive individuals
Speculative / Theoretical Long-Term Concerns:
  • •Prolonged bleeding time in perioperative contexts

Under-Researched Populations (Evidence Gaps)

Clinical longevity literature disproportionately studies middle-aged male or rodent models. Exercise caution in:

  • Patients with severe renal impairment (eGFR < 30)
Biochemical Synergies & Antagonisms

Biological Relationship Graph

Compounding Multiplier: 1.25x
Works Well With (Compounding Synergies)

Combines safely with baseline longevity routines.

May Interfere With (Antagonisms / Blunting)

No direct clinical antagonisms detected.

Structured N=1 Real-World Evidence (RWE)

Community Biomarker Reviews (0)